Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 40.69 | 39.03 | 27.72 | 21.32 | 21.53 | 17.40 | 14.35 | 26.12 | 33.52 | 14.22 | 96.38 | 55.01 | 26.87 | 125.51 | 2.37 | 5.53 | 36.28 | 32.30 | 50.71 | 82.09 | 99.38 |
| — | +124.3% | +93.1% | -18.4% | -35.8% | +22.4% | -85.1% | -52.5% | +24.7% | -88.7% | +3968.1% | +895.0% | -25.9% | +288.6% | -95.3% | -93.3% | -63.5% | -78.8% | -70.7% | -34.3% | -13.5% | |
| P/B Ratio | 1.33 | 2.12 | 0.80 | 0.56 | 0.64 | 0.51 | 0.32 | 0.61 | 1.14 | 0.97 | 1.74 | 1.00 | 0.52 | 1.07 | 1.17 | 2.03 | 4.20 | 4.13 | 5.90 | 8.26 | 7.74 |
| — | +317.1% | +147.2% | -7.6% | -43.7% | -47.7% | -81.4% | -39.1% | +119.3% | -9.3% | +48.8% | -50.6% | -87.6% | -74.1% | -80.2% | -75.4% | -45.8% | -62.1% | -39.5% | -60.0% | -5.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -94.1% | 100.0% | -124.6% | 100.0% | -1384.1% | -100.4% | -1688.6% | -821.5% | -1027.2% | 30.3% | -150.4% | -191.5% | -143.8% | -4281.1% | -11.3% | -96.6% | -432.8% | -338.3% | -291.8% | -307.3% | -273.5% |
| — | +199.6% | +92.6% | +112.2% | -34.7% | -431.4% | -1022.4% | -329.0% | -614.2% | +100.7% | -1234.5% | -98.3% | +66.8% | -1165.3% | +96.1% | +68.6% | -58.2% | -31.1% | +3.6% | -111.6% | +10.7% | |
| Operating Margin | -2222.4% | -1495.4% | -2540.4% | -2536.2% | -1995.1% | -1938.5% | -2534.1% | -3319.8% | -1703.9% | -665.7% | -2652.9% | -2868.4% | -2637.8% | -6705.8% | -48.5% | -145.2% | -576.7% | -448.1% | -404.4% | -406.5% | -384.0% |
| — | +22.9% | -0.3% | +23.6% | -17.1% | -191.2% | +4.5% | -15.7% | +35.4% | +90.1% | -5372.4% | -1875.1% | -357.4% | -1396.7% | +88.0% | +64.3% | -50.2% | -28.5% | +2.5% | -93.5% | +7.8% | |
| Net Margin | -2051.1% | -1448.6% | -2402.8% | -2364.8% | -1852.4% | -1786.6% | -2309.5% | -2803.9% | -1551.0% | -567.4% | -2493.7% | -2632.6% | -2323.6% | -5654.3% | -32.0% | -127.1% | -557.8% | -410.3% | -356.7% | -402.0% | -304.4% |
| — | +18.9% | -4.0% | +15.7% | -19.4% | -214.8% | +7.4% | -6.5% | +33.2% | +90.0% | -7689.8% | -1971.8% | -316.6% | -1278.1% | +91.0% | +68.4% | -83.2% | +0.2% | +11.8% | -20.3% | +60.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -51.8% | -18.1% | -16.1% | -14.7% | -13.0% | -12.4% | -12.4% | -15.3% | -12.6% | -9.3% | -12.1% | -11.4% | -10.7% | -11.5% | -3.9% | -11.3% | -15.2% | -12.5% | -10.0% | -9.7% | -5.8% |
| — | -46.1% | -30.2% | +4.2% | -3.7% | -32.7% | -2.6% | -33.8% | -16.8% | +19.0% | -207.6% | -1.7% | +29.4% | +8.1% | +60.8% | -15.5% | -160.4% | -75.4% | -30.4% | +25.8% | +55.3% | |
| ROA | -35.9% | -11.1% | -10.3% | -9.8% | -9.0% | -8.8% | -9.0% | -11.1% | -9.3% | -7.0% | -8.9% | -8.4% | -8.0% | -8.7% | -2.8% | -7.7% | -10.7% | -9.1% | -7.4% | -7.2% | -4.3% |
| — | -25.1% | -15.3% | +12.3% | +3.2% | -26.5% | -0.5% | -32.6% | -16.4% | +19.4% | -215.6% | -8.5% | +25.5% | +5.0% | +61.7% | -7.6% | -148.0% | -70.9% | -36.6% | +15.3% | +52.8% | |
| ROIC | -36.5% | -11.3% | -10.9% | -10.2% | -9.1% | -8.8% | -8.9% | -11.7% | -8.9% | -7.8% | -9.2% | -8.0% | -7.9% | -9.0% | -4.0% | -9.0% | -10.9% | -9.4% | -8.3% | -7.6% | -5.5% |
| — | -27.9% | -22.0% | +12.9% | -2.1% | -13.2% | +2.6% | -46.8% | -12.3% | +13.6% | -129.4% | +11.0% | +27.7% | +4.5% | +52.1% | -17.9% | -99.8% | -112.8% | -33.1% | +28.0% | +67.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.38 | 0.49 | 0.43 | 0.38 | 0.34 | 0.31 | 0.29 | 0.27 | 0.27 | 0.25 | 0.24 | 0.28 | 0.26 | 0.24 | 0.23 | 0.23 | 0.21 | 0.19 | 0.18 | 0.17 | 0.15 |
| — | +58.5% | +47.9% | +40.5% | +23.9% | +22.8% | +20.6% | -4.8% | +4.8% | +4.3% | +6.3% | +24.4% | +21.7% | +25.6% | +25.8% | +33.6% | +43.4% | +31.7% | +27.7% | -33.2% | -25.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.79 | 4.85 | 5.85 | 5.79 | 7.87 | 8.04 | 8.81 | 7.58 | 8.29 | 9.18 | 8.69 | 8.48 | 8.81 | 8.78 | 9.00 | 4.40 | 5.15 | 6.55 | 7.69 | 7.79 | 7.55 |
| — | -39.7% | -33.6% | -23.6% | -5.1% | -12.5% | +1.4% | -10.6% | -5.9% | +4.6% | -3.4% | +92.6% | +71.1% | +34.0% | +17.1% | -43.5% | -31.8% | -3.1% | -9.6% | +34.9% | -17.6% | |
| Quick Ratio | 5.79 | 4.85 | 5.85 | 5.79 | 7.87 | 8.04 | 8.81 | 7.58 | 8.29 | 9.18 | 8.69 | 8.48 | 8.81 | 8.78 | 9.00 | 4.40 | 5.15 | 6.55 | 7.69 | 7.79 | 7.55 |
| — | -39.7% | -33.6% | -23.6% | -5.1% | -12.5% | +1.4% | -10.6% | -5.9% | +4.6% | -3.4% | +92.6% | +71.1% | +34.0% | +17.1% | -43.5% | -31.8% | -3.1% | -9.6% | +34.9% | -17.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FATE stock.
Fate Therapeutics, Inc.'s current P/E is -2.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Fate Therapeutics, Inc.'s current operating margin is -2222.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Fate Therapeutics, Inc.'s business trajectory between earnings reports.